Status:
NOT_YET_RECRUITING
Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
Lead Sponsor:
Xinxin Zhang
Conditions:
Rhabdomyosarcoma
Eligibility:
All Genders
6+ years
Phase:
EARLY_PHASE1
Brief Summary
An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma
Eligibility Criteria
Inclusion
- Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing;
- Age ≥ 6 years;
- No known effective treatment available or no treatment proven to prolong survival with an acceptable quality of life;
- Expected survival time greater than 6 months;
- ECOG performance status score of 0-1; -
Exclusion
- History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT06932861
Start Date
May 1 2025
End Date
May 1 2028
Last Update
April 22 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.